About Us

Revolutionizing gene therapies

Gene therapy—delivering a gene into specific cell types so that its expression can treat or cure a disease—is a concept that dates back more than three decades. The field has shown tremendous potential and has now produced approved products that have helped many patients. However, the development of new gene therapies has been beset by safety issues, technical obstacles, and manufacturing cost challenges that have so far restricted their use to a small subset of diseases. It is increasingly accepted that the limitations of current gene therapy approaches are often related to the use of adeno-associated viral vectors (AAVs) or other viral vectors to deliver the genetic material.

Intergalactic Therapeutics was founded by ATP (Apple Tree Partners), a leading life sciences venture capital firm, to overcome the limitations of viral-based gene therapy and develop a best-in-class non-viral alternative. Intergalactic uses synthetic biology and engineered gene circuits to make covalently closed and circular DNA (“C3DNA”) molecules designed to deliver a potentially safer and more effective solution for patients.

Intergalactic’s approach promises benefits beyond patient safety. Our customizable C3DNA format offers the versatility to treat a broad range of diseases, and its synthetic construction allows simpler, faster, and more cost-efficient production.

Our Science


Michael Ehlers, M.D., Ph.D.

Chief Executive Officer

José Lora, Ph.D.

Chief Scientific Officer

Eileen Higham, Ph.D.

Senior Vice President,
Head of Technical Operations

Vincent Hennemand

Chief Operating Officer

Robert Farra, M.S.

Chief Engineer,
Head of Device Development

Gayathri Ramaswamy, Ph.D.

Vice President,
Drug Discovery and Disease Biology

Michael McHugh, Ph.D, J.D.

Head of Intellectual Property

Jodi Kennedy, Ph.D.

Senior Director,
Molecular Design & Delivery

Kimberly McGonagle

Senior Director,
Human Resources

Marina Feschenko, Ph.D.

Senior Director,
Analytical Development

Board of Directors

Seth Harrison, M.D.

ATP Founder and Managing Partner

Anna Batarina

ATP Partner

Michael Ehlers, M.D., Ph.D.

ATP Chief Scientific Officer and Venture Partner

Scientific Advisory Board

Ulrich von Andrian, M.D., Ph.D.

Mallinckrodt Professor of Immunopathology at Harvard Medical School Program Leader, Basic Immunology at Ragon Institute of MGH, MIT and Harvard

Thaddeus Dryja, M.D.

Professor of Ophthalmology, Harvard Medical School

Francisco Quintana, Ph.D.

Professor of Neurology at the Center for Neurologic Diseases at Brigham and Women’s Hospital, Harvard Medical School

Associate Member at the Broad Institute of Harvard and MIT

Weiping Zou, M.D., Ph.D.

Director of the Michigan Center of Excellence for Cancer Immunology and Immunotherapy, Co-Director of the Cancer Hematopoiesis and Immunology Program, and Director of the Immunologic Monitoring Core at University of Michigan School of Medicine and Rogel Cancer Center